Advanced Medical Solutions gets CE-mark for foam dressing
The AIM-traded firm said the product would be commercialised via its network of wound care partners and distributors in CE-mark markets.
It described the PHMB Foam Dressing as a polyurethane foam impregnated with polyhexamethylene biguanide, along with an atraumatic perforated silicone wound contact layer.
The dressing was indicated for use in the management of various wounds including pressure sores, diabetic ulcers, post-op surgical wounds and burns.
It said the product could manage wound exudate as well as microbial contamination, with the atraumatic silicone layer reducing wound pain during healing and dressing changes.
The dressing had been shown to be highly effective against methicillin-resistant staphylococcus aureus (MRSA) and a "broad spectrum" of microbes, with in vitro testing demonstrating total eradication of MRSA, MRSE, and E. coli within 24 hours, compared to market-leading silver products which failed to achieve that within seven days.
"This new product approval in Europe for Silicone PHMB Foam Dressing further strengthens AMS's advanced wound care portfolio in Europe and reinforces the fact that our research and development and regulatory capabilities are a key pillar of our organic growth strategy," said chief executive officer Chris Meredith.
At 15490 GMT, shares in Advanced Medical Solutions Group were down 0.22% at 230p.